<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ECC976E7-B6C0-415D-A8FA-FCBF275E7D27"><gtr:id>ECC976E7-B6C0-415D-A8FA-FCBF275E7D27</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2313C693-6B5F-4A48-90C5-90D57FC2D64B"><gtr:id>2313C693-6B5F-4A48-90C5-90D57FC2D64B</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Rubinsztein</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0000872"><gtr:id>3A8C71F0-F778-4B5A-9EB2-EBF67EF5540A</gtr:id><gtr:title>Dissection of pathways involved in polyglutamine disease pathogenesis- identification and analyses of modifier genes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0000872</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>806354</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Wyeth Pharmaceuticals</gtr:department><gtr:description>Testing rapamycin analogues in neurodegenerative diseases</gtr:description><gtr:id>DEA2B936-F28E-460B-9E3D-7C6A1AF27CDF</gtr:id><gtr:impact>Berger, B Ravikumar, FM. Menzies, L Garcia Oroz, BR Underwood, MN Pangalos, I Schmitt, U Wullner, BO Evert, CJ O'Kane, and DC Rubinsztein (2006). Rapamycin alleviates toxicity of different aggregate-prone proteins. Human Molecular Genetics 15:433-442</gtr:impact><gtr:outcomeId>FF75123B731-1</gtr:outcomeId><gtr:partnerContribution>Collaboration</gtr:partnerContribution><gtr:piContribution>We are testing rapamycin analogogues for therapeutic efficacy in mouse models of different neurodegenrative diseases</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit - Cambridge</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DBCCE037-C8D8-494F-97A9-DE8D14F18DF3</gtr:id><gtr:impact>talk to school class

good feedback from students</gtr:impact><gtr:outcomeId>DD894EC7160</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2968260</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>907ED2A6-BF3D-47D4-84A7-56B7341DAD25</gtr:id><gtr:outcomeId>F30E089D9CC0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of autophagy upregulation for treating neurodegenerative diseases</gtr:description><gtr:grantRef>G0000872</gtr:grantRef><gtr:id>7FA9A404-5F97-47E5-8EB9-93E3F9BC913F</gtr:id><gtr:impact>USA patent</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>25402ADB3B9</gtr:outcomeId><gtr:patentId>US2007155771</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Methods and Means for Treating Protein Conformational Disorders.</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Use of autophagy inducing drugs for neurodegenerative diseases</gtr:description><gtr:id>8158A82A-5D0D-433E-A24F-063F3BDF39C4</gtr:id><gtr:impact>Currently we are providing proof to expand the use of this strategy beyong Huntington disease</gtr:impact><gtr:outcomeId>99AF5675873</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Use of autophagy inducing drugs for neurodegenerative diseases</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DA3CE9E3-04E0-4DEA-B908-BC7474E5B636</gtr:id><gtr:title>Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e37ccdf18bdd285bcfcc43e4b36e6050"><gtr:id>e37ccdf18bdd285bcfcc43e4b36e6050</gtr:id><gtr:otherNames>Vacher C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>B37371C05F8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>779D9B9E-C6D3-48E3-A1CF-B369C5367A55</gtr:id><gtr:title>Rapamycin alleviates toxicity of different aggregate-prone proteins.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f21a3f64d95852bb3cb8f623a1e9dc44"><gtr:id>f21a3f64d95852bb3cb8f623a1e9dc44</gtr:id><gtr:otherNames>Berger Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>09ABAEC0D76</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9554035F-81AC-417D-A9FB-83054549C306</gtr:id><gtr:title>Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84299561b806b1664b65dc87dd000920"><gtr:id>84299561b806b1664b65dc87dd000920</gtr:id><gtr:otherNames>Luo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>474B29EFD15</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>062AE2E0-AEDB-4539-A81E-9D2ABBEF9800</gtr:id><gtr:title>Rapamycin pre-treatment protects against apoptosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c684afaa55830b389d7cc1f42d26dc86"><gtr:id>c684afaa55830b389d7cc1f42d26dc86</gtr:id><gtr:otherNames>Ravikumar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>C81C28B0239</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58FC706F-680C-4885-8393-D25CD6FEFCD9</gtr:id><gtr:title>The roles of intracellular protein-degradation pathways in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fc15ca02a98b8ae96b659614dbdd5b8"><gtr:id>2fc15ca02a98b8ae96b659614dbdd5b8</gtr:id><gtr:otherNames>Rubinsztein DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>728AD550617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92014CCF-CF55-48E9-A3DB-B9E79C10FCE9</gtr:id><gtr:title>Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b957f5c686493ef530aa6c8d8777989"><gtr:id>1b957f5c686493ef530aa6c8d8777989</gtr:id><gtr:otherNames>Underwood BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>8CEE47F03A7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB85D619-F994-465C-80D1-5F8169EFA6CC</gtr:id><gtr:title>Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f21a3f64d95852bb3cb8f623a1e9dc44"><gtr:id>f21a3f64d95852bb3cb8f623a1e9dc44</gtr:id><gtr:otherNames>Berger Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>26094FBE643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C65FE7DF-E05B-4A2F-85EE-B528D1DB22E1</gtr:id><gtr:title>Lithium induces autophagy by inhibiting inositol monophosphatase.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/caf3d032b5e39560b0be5e4330259686"><gtr:id>caf3d032b5e39560b0be5e4330259686</gtr:id><gtr:otherNames>Sarkar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>D33FFCC9059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>342C57EF-C9C6-4EE5-A48C-52ACDA7F9705</gtr:id><gtr:title>Protective roles for induction of autophagy in multiple proteinopathies.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68d9bd81131c2ef85da0b3bb510c1948"><gtr:id>68d9bd81131c2ef85da0b3bb510c1948</gtr:id><gtr:otherNames>Menzies FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>585d4eee9d5d19.99379567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC5ACDC8-6270-48A9-9C0C-B7546B369553</gtr:id><gtr:title>Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/caf3d032b5e39560b0be5e4330259686"><gtr:id>caf3d032b5e39560b0be5e4330259686</gtr:id><gtr:otherNames>Sarkar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>3DF254A3799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE03E2F4-5B78-4C96-8573-DFAF6E7EAC86</gtr:id><gtr:title>Deleterious and protective properties of an aggregate-prone protein with a polyalanine expansion.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f21a3f64d95852bb3cb8f623a1e9dc44"><gtr:id>f21a3f64d95852bb3cb8f623a1e9dc44</gtr:id><gtr:otherNames>Berger Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>99F4E8B7DA1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F99D8CA-1211-473D-813D-310F63B52777</gtr:id><gtr:title>Dynein mutations impair autophagic clearance of aggregate-prone proteins.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c684afaa55830b389d7cc1f42d26dc86"><gtr:id>c684afaa55830b389d7cc1f42d26dc86</gtr:id><gtr:otherNames>Ravikumar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>37231D071D4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9052CB9A-0C32-4031-8370-252A8464A94A</gtr:id><gtr:title>Role of autophagy in the clearance of mutant huntingtin: a step towards therapy?</gtr:title><gtr:parentPublicationTitle>Molecular aspects of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c684afaa55830b389d7cc1f42d26dc86"><gtr:id>c684afaa55830b389d7cc1f42d26dc86</gtr:id><gtr:otherNames>Ravikumar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0098-2997</gtr:issn><gtr:outcomeId>58670F47CC3</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0000872</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>